mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan

The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.

Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.